Australia launches national review of puberty blocker guidelines

The Australian federal government has taken action. Health Minister Mark Butler has formally asked the National Health and Medical Research Council (NHMRC) to urgently provide advice on the safety of puberty blockers for minors with gender dysphoria. That advice is intended to form the basis for new, nationwide treatment standards — a process expected to run until 2028. Until then, the 2018 guideline issued by Melbourne’s Royal Children’s Hospital (RCH), since only lightly updated to version 1.5, will remain the de facto national standard.

What exactly the minister is asking for

Butler’s request uses unusually direct language for a minister who generally avoids becoming involved in medical matters. This is not a non-binding review, but a request for the NHMRC to assess whether current practice remains sustainable and then develop national standards to replace Australia’s highly regionally fragmented youth gender care. Each state and hospital currently operates largely under its own protocol, with the RCH Melbourne guideline serving as the most influential example — including outside Victoria.

A guideline that missed the international reassessment

The fact that the RCH guideline has barely been updated since 2018 is striking, because other parts of the world have made significant changes in recent years. In the United Kingdom, the four-year Cass Review concluded in 2024 that the scientific evidence supporting puberty blockers for young people is weak. Paediatrician Hilary Cass put it this way: "I cannot think of another situation in medicine where we give life-changing treatments without having a clear understanding of the risks and benefits." The then British Health Minister added that there was "insufficient evidence about the long-term effects of puberty blockers... that evidence should have been available before they were ever prescribed."

Sweden and Finland moved ahead of Australia: both countries had already restricted the use of puberty blockers outside research settings after their own systematic literature reviews reached conclusions similar to those of the Cass Review. Germany received a new guideline in 2025, but its own psychiatric professional association raised critical concerns about it: the guideline, it argued, failed to answer the "medical and ethical questions" needed to protect minors. Australia’s announcement therefore does not put it at the forefront, but rather closes a gap that international observers have been highlighting for some time.

Why the comparison with Melbourne is problematic

The RCH Melbourne guideline dates from a period when the so-called affirmative model was rarely questioned. Since then, referrals to gender clinics have also risen sharply in Australia, while the underlying evidence base — consisting largely of the same small, methodologically weak cohort studies highlighted by the Cass Review — has not kept pace. What this can mean in practice became clear from the review of the gender clinic in Cairns. A guideline that is not revised while scientific uncertainty is increasing creates a false sense of security for clinicians and parents: the impression of an established medical consensus, when in reality there is growing international doubt. For a detailed comparison of puberty blocker guidelines worldwide, including the Swedish and Finnish reconsiderations, the overview on puberteitsremmers.nl is a good starting point.

What needs to happen before 2028

Until the NHMRC produces new standards, current practice in Australia will remain unchanged — including the RCH guideline that formed the basis for thousands of referrals. Critics point out that a process lasting several years is a long time for children and young people who are entering the system now: they are receiving care based on a guideline whose original authors can no longer stand behind its recommendations with the same degree of certainty following the Cass Review. For the Netherlands, where the Dutch Protocol occupies a similar position as the foundation of care, Australia’s move is another sign that the scientific basis for puberty blockers is increasingly being explicitly questioned internationally by governments themselves, not only by external critics.

Sources

Bernard Lane, "Guidelines in the balance", Gender Clinic News, 24 May 2026: genderclinicnews.com/p/guidelines-in-the-balance.